Business Wire

Five-Time Olympic Medalist Gabby Thomas Joins Amazfit as Athlete Ambassador

13.2.2025 19:00:00 EET | Business Wire | Press release

Share

Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), is proud to announce five-time Olympic Medalist and fashion icon, Gabby Thomas, as the latest ambassador to join the brand's growing roster of elite athletes. As part of the four-year partnership, Thomas will wear Amazfit smartwatches both on the track during training and in competition, and off the track to monitor sleep and recovery. Moreover, through the Zepp app-based food log, Gabby will have easy access to nutrition-tracking as well.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213824479/en/

Five-time Olympic Medalist and fashion icon, Gabby Thomas, is the latest ambassador to join Amazfit's growing roster of elite athletes. (Graphic: Business Wire)

As the 200m, 4x100m and 4x400m gold medalist, Thomas left the 2024 Paris Olympics as the most decorated U.S. track and field athlete at the Games. Additionally, she holds multiple Diamond League titles and took home two additional Olympic medals - 200m (bronze) and 4x100m (silver) - at the 2020 Tokyo Games. The partnership with Amazfit is Thomas’ first with a smartwatch and gives credence to the benefits data can play on athletic performance.

“I’m really excited to partner with Amazfit because, for me, the little things make all the difference,” said Thomas. “As an athlete, this is the exact type of partnership that will help me continue to get better. It's so important to have objective data on my body—whether it’s tracking my heart rate during a workout, seeing how well I’ve recovered, or understanding how much quality sleep I’m getting. Having a reliable smart wearable brand like Amazfit in my corner is a game-changer."

As part of this exciting partnership, Thomas will enhance her training by incorporating Amazfit's smart wearables analysis into her preparation and recovery to improve performance and help break future records. She will also provide insights and feedback to Amazfit’s development and design teams on product future features and styles.

"We are honored to have Gabby join the Amazfit team," said Wayne Huang, Founder & CEO, Zepp Health. "Her remarkable athletic career and passion for style align closely with our mission to unlock the limits of human potential to ‘Discover Amazing.’ Through this partnership, we will continue to empower athletes to unleash their full potential by rewriting the record books utilizing our advanced smart wearables ecosystem."

Amazfit is committed to creating products that empower holistic health and well-being, and that healthy living requires balance across four key pillars of wellness: physical fitness, sleep, mindfulness and nutrition. Amazfit’s diverse product portfolio includes Active, Cheetah and T-Rex series performance smartwatches, Helio smart ring and the Zepp App, all designed to help athletes and health enthusiasts track and enhance their holistic health. The Zepp App’s latest Food Log feature offers athletes like Thomas an unparalleled ability to bridge the gap between nutrition and fitness, ensuring peak performance and optimal recovery. Whether monitoring heart rate, tracking sleep cycles, or logging meals, Amazfit provides the insights needed to maintain a well-rounded approach to health.

Thomas joins a growing list of Amazfit athletes, including HYROX World Champions Meg Jacoby and Hunter McIntyre, Padel star Bea González and Olympians Morgan Pearson (triathlon) and Yemaneberhan "Yeman" Crippa (5k & 10k).

Explore the full range of Amazfit smart wearables and experience innovation that elevates performance, recovery, and precision at www.amazfit.com.

For more information, please visit Amazfit.com and follow us on Facebook, Instagram, Twitter and YouTube.

About Amazfit

Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company. Offering a wide selection of smartwatches and bands, Amazfit's brand tagline "Discover Amazing", encourages individuals to break their barriers, and exceed expectations while finding joy in every moment.

Amazfit is powered by Zepp Health's proprietary health management platform that delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. With outstanding craftsmanship, Amazfit smartwatches have won many design awards, including the iF Design Award and the Red Dot Design Award.

Launched in 2015, Amazfit is today embraced by millions of users. Its products are available in more than 90 countries across the Americas, EMEA, and APAC regions. For more information about Amazfit, visit www.amazfit.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213824479/en/

Contacts

MEDIA CONTACT
Mary Thompson Woodbury
mary.woodbury@zepp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye